Prostate Cancer International is
for 2011 by Great NonProfits
The Agency for Healthcare Research and Quality (AHRQ) has released a draft version of a detailed techology assessment report entitled, “Comparative evaluation of radiation treatments for clinically localized prostate cancer: an update.”
Filed under: Management, Treatment | Tagged: first line, localized, outcomes, radiation therapy | Leave a Comment »
Today’s news reports include commentary on studies dealing with: Whether RALP outcomes are really comparable to those from RRP Surgical expertise, surgical caseload, and pelvic lymphadenectomy in treatment of intermediate- and high-risk prostate cancer Sexual function after first-line treatment with SBRT (CyberKnife) Distinguishing true biochemical recurrence from a PSA “bounce” after 125I-based prostate brachytherapy
Filed under: Management, Treatment | Tagged: bounce, CyberKnife, ED, failure brachytherapy, LRP, lymphadenextomy, outcomes, PSA, RALP, robot-assisted laparoscopic prostatectomy, SBRT, sexual function, stereotactic body radiotherapy | Leave a Comment »
It has long been known that patient outcomes and complications after prostate surgery vary among surgeons to a greater extent than may be accounted for by chance.
Filed under: Management, Treatment | Tagged: heterogeneity, outcomes, radical prostatectomy | 6 Comments »
Today’s news reports summarize papers recently published on: Optimism, pessimism, and long-term health outcomes External beam radiation + hormone therapy for high-risk patients Quality of life and health utility after radical prostatectomy Paclitaxel + estradiol combination therapy in men progressing after docetaxel-based chemotherapy
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", estradiol, hormone therapy, HRQOL, optimism, outcomes, paclitaxel, pessimism, quality of life, radiation, radical prostatectomy | Leave a Comment »
The “game” of retrospectively analyzing every possible piece of data from the European Randomized Screening Study for Prostate Cancer (ERSPC) has been under way for a while now … and we can expect this game to produce lots and lots of controversial information and media coverage. But much of the data from these subset analyses [...]
Filed under: Diagnosis, Risk | Tagged: biopsy, false positive, negative, outcomes, screening | 8 Comments »
Today’s news reports address studies dealing with the following issues: Re-validation of the PCPT-based prostate cancer risk calculator in contemporary patients Can the SPECT/CT-enhanced Prostascint test replace prostate biopsy? Who should be eligible for active surveillance protocols? Predicting survival of hormone-refractory patients progressing after first-line, docetaxel-based chemotherapy
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Tagged: active surveillance, chemotherapy, grading, outcomes, Prostascint, risk calculator | 3 Comments »
A new paper by Armstrong et al. has analyzed data from the original TAX327 clinical trial in an attempt to define specific patient “risk groups” based on the participants in that trial and how they responded to docetaxel-based chemotherapy.
Filed under: Management, Treatment | Tagged: chemotherapy, docetaxel, outcomes, reponse, risk groups | Leave a Comment »
Isbarn et al. (a German group working in Hamburg) have reported the first long-term survival data in response to radical prostatectomy (RP) from a European country since the beginning of the PSA era.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: long-term, outcomes, PSA era, radical prostatectomy | 2 Comments »
Who is really a candidate for active surveillance (AS) as opposed to early treatment for prostate cancer that is supposedly localized is not yet well-defined. Indeed, it may not even be possible to come up with any “absolute” guidelines for eligibility for AS based on the diagnostic and prognostic tools we have at this time.
Filed under: Management | Tagged: active surveillance, expectant managemt, outcomes | 4 Comments »
As a follow-up to yesterday’s report on Scardino’s presentation to the New York section of the AUA, it is worth noting a publication last November from Johns Hopkins. The research group’s goal was to investigate long-term survival following radical prostatectomy as first-line treatment in their patients with high-risk prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", outcomes, radical prostatectomy, surgery | 6 Comments »
In today’s prostate cancer news reports there are brief comments on a number of interesting (if technically dense) articles dealing with such topics as: The need for regularity of post-treatment PSA testing Surgical outcomes of men with Gleason 8-10 disease over 20 years of experience Loss of penile length after radical prostatectomy Does bladder cancer invasion meet [...]
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: frequency, Gleason 8-10, outcomes, post-surgery, PSA, stage T4 | 3 Comments »
A few days ago we reported on a study which concluded that the addition of high-dose-rate (HDR) brachytherapy to intensity-modulated radiation therapy (IMRT) had limited short-term clinical benefit in the treatment of localized prostate cancer compared to IMRT alone. Newly published Australian data is arguably supportive of this viewpoint.
Filed under: Management, Treatment | Tagged: 3D-CRT, brachytherapy, conformational radiation therapy, HDR, high-dose-rate, outcomes, three-dimensional | Leave a Comment »
An article by Hu et al. in the Journal of the American Medical Association this week is getting a lot of media visibility. (See for example the report from the Associated Press.) The “New” Prostate Cancer InfoLink thinks the article says more about the skills of individual surgeons than it does about the techniques and [...]
Filed under: Uncategorized | Tagged: open, outcomes, RALP, robot, RRP, surgery | 2 Comments »
In today’s news reports we note items on: DNA histone levels and adverse prognosis Outcomes to active surveillance vs EBRT The use of radiation therapy as first-line treatment over time Prostate cancer-specific mortality, brachytherapy, and EBRT
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, histones, outcomes, prognosis, radiotherapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site